Xie Zijun, Yin Xiaoyu, Gong Bo, Nie Wenjing, Wu Bin, Zhang Xuchao, Huang Jian, Zhang Pingyou, Zhou Zhiwei, Li Zijun
Department of Gastroenterology, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou City, Guangdong Province, China. Department of Gastroenterology, The Third Affiliated Hospital of Sun Yat-sen University, Sun Yat-sen University, Guangzhou City, Guangdong Province, China.
Department of Gastrointestinal Surgery, The First Affiliated Hospital of Sun Yat-sen University, Sun Yat-sen University, Guangzhou City, Guangdong Province, China.
Cancer Prev Res (Phila). 2015 Feb;8(2):165-73. doi: 10.1158/1940-6207.CAPR-14-0192. Epub 2014 Dec 23.
Early surgery is vital in the treatment of pancreatic cancer, which is often fatal. However, there is currently no useful noninvasive biomarker to screen for pancreatic cancer. Studies have documented that many salivary molecules can be used to detect systemic diseases. We investigated whether salivary miRNAs are useful biomarkers for detecting resectable pancreatic cancer. Using an Agilent microarray, salivary miRNAs were profiled from saliva samples of 8 patients with resectable pancreatic cancer and 8 healthy controls. Candidate biomarkers identified in the profiles were subjected to validation using quantitative PCR and an independent sample set of 40 patients with pancreatic cancer, 20 with benign pancreatic tumors (BPT), and 40 healthy controls. The validated salivary miRNA biomarkers were evaluated within three discriminatory categories: pancreatic cancer versus healthy control, pancreatic cancer versus BPT, and pancreatic cancer versus noncancer (healthy control + BPT). miR-3679-5p showed significant downregulation in the pancreatic cancer group within the three categories (P = 0.008, 0.007, and 0.002, respectively), whereas miR-940 showed significant upregulation in pancreatic cancer (P = 0.006, 0.004, and 0.0001, respectively). Logistic regression models combining the two salivary miRNAs were able to distinguish resectable pancreatic cancer within the three categories, showing sensitivities of 72.5%, 62.5%, and 70.0% and specificities of 70.0%, 80.0%, and 70.0%, respectively. Salivary miR-3679-5p and miR-940 possess good discriminatory power to detect resectable pancreatic cancer, with reasonable specificity and sensitivity. This report provides a new method for the early detection of pancreatic cancer and other systemic diseases by assessing salivary miRNAs.
早期手术对于胰腺癌的治疗至关重要，胰腺癌通常是致命的。然而，目前尚无有用的非侵入性生物标志物来筛查胰腺癌。研究表明，许多唾液分子可用于检测全身性疾病。我们研究了唾液微小RNA（miRNA）是否为检测可切除胰腺癌的有用生物标志物。使用安捷伦微阵列对8例可切除胰腺癌患者和8例健康对照者的唾液样本进行miRNA谱分析。对谱中鉴定出的候选生物标志物，使用定量PCR以及由40例胰腺癌患者、20例胰腺良性肿瘤（BPT）患者和40例健康对照组成的独立样本集进行验证。在胰腺癌与健康对照、胰腺癌与BPT、胰腺癌与非癌症（健康对照+BPT）这三个区分类别中对经过验证的唾液miRNA生物标志物进行评估。miR-3679-5p在这三个类别中的胰腺癌组中均显示出显著下调（分别为P = 0.008、0.007和0.002），而miR-940在胰腺癌中显示出显著上调（分别为P = 0.006、0.004和0.0001）。结合这两种唾液miRNA的逻辑回归模型能够在这三个类别中区分可切除胰腺癌，敏感性分别为72.5%、62.5%和70.0%，特异性分别为70.0%、80.0%和70.0%。唾液miR-3679-5p和miR-940在检测可切除胰腺癌方面具有良好的区分能力，特异性和敏感性合理。本报告通过评估唾液miRNA为早期检测胰腺癌及其他全身性疾病提供了一种新方法。
